



January 17, 2014

The Honorable Eileen Cody  
Chair  
House Health Care & Wellness Committee  
Washington State Legislature  
303 John L. O'Brien Building  
PO Box 40600  
Olympia, WA 98504-0600

Re: AMA support for House Bill 2326, "An Act relating to the prescription of biological products and interchangeable biological products"

Dear Chairwoman Cody:

On behalf of the American Medical Association (AMA) and our physician and student members, I am writing in support of House Bill 2326, "An Act relating to the prescription of biological products and interchangeable biological products." The AMA supports this bill because it safeguards patient safety while simultaneously ensuring that physicians retain their prescribing autonomy.

**AMA supports physician discretion and substitution limited to interchangeable biosimilars**

As noted in the bill, biologics comprise a wide range of products, including vaccines, blood and blood components, allergenic extracts, human cells or tissue intended for implantation, transplantation, infusion or transfer into human recipients and more. These represent a complex array of pharmaceutical products, and current legislation governing generic substitution may not be adequate to address the unique nature of biologics.

Under current federal regulations, a sponsor may seek approval of a "biosimilar" product under section 351(k) of the Public Health Service Act which establishes an abbreviated approval pathway for biological products that are either "highly similar" (i.e., biosimilar) to, or further demonstrated to be "interchangeable" with, an FDA-licensed biological product. The AMA agrees that substitution should be limited to only those biosimilar biologic products deemed "interchangeable" by the FDA. Please note that there is no such thing as a generic biologic.

The Honorable Eileen Cody  
January 17, 2014  
Page 2

Further, physicians should retain authority to designate whether a brand name reference product is dispensed. If the physician – based on medical research and his or her experience – prefers the brand product, then the physician can help protect his or her patients by ensuring that the specific brand is prescribed. Pharmacists should only be allowed to substitute an interchangeable – and only an interchangeable – biologic product as defined by 42 U.S.C. §262(k)(4), when prescribers authorize substitution or fail to indicate a preference. This bill accomplishes that important balance.

For the aforementioned reasons, the AMA supports House Bill 2326. If you have any questions, please feel free to contact Daniel Blaney-Koen, JD, Senior Legislative Attorney, Advocacy Resource Center, at [daniel.blaney-koen@ama-assn.org](mailto:daniel.blaney-koen@ama-assn.org) or (312) 464-4954.

Thank you for your efforts on this important public health issue.

Sincerely,

A handwritten signature in cursive script, appearing to read "James L. Madara".

James L. Madara, MD

cc: Washington State Medical Association  
Representative Marcus Riccelli  
Representative Joe Schmick